Trial Outcomes & Findings for Effect of Peri-operative Supplemental Oxygen in Wound Infection After Appendectomy (NCT NCT02687217)
NCT ID: NCT02687217
Last Updated: 2016-05-06
Results Overview
ASEPSIS score- Additional treatment; Serous discharge; Erythema; Purulent exudate; Separation of deep tissues; Isolation of bacteria; and Stay. A daily score of 20 or more considered evidence of infection. Category of infection: Total score of 0-10 satisfactory healing; 11-20 disturbance of healing; 21-30 minor wound infection; 31-40 moderate wound infection; \> 40 severe wound infection.
COMPLETED
NA
60 participants
14 days
2016-05-06
Participant Flow
Participant milestones
| Measure |
Group A: Control
Group A: Control- Received no supplemental oxygen throughout the surgery and received oxygen at 4l/min. in 2hrs postoperatively
|
Group B: Test
Group B: Test- Received hyperoxygenation more than or equal to 50% throughout the surgery and received oxygen at 6l/min. upto 2 hrs postoperatively.
oxygen: Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery.
|
|---|---|---|
|
Overall Study
STARTED
|
30
|
30
|
|
Overall Study
COMPLETED
|
30
|
30
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Effect of Peri-operative Supplemental Oxygen in Wound Infection After Appendectomy
Baseline characteristics by cohort
| Measure |
Group A: Control
n=30 Participants
Group A: Control- Received no supplemental oxygen throughout the surgery and received oxygen at 4l/min. in 2hrs postoperatively
|
Group B: Test
n=30 Participants
Group B: Test- Received hyperoxygenation more than or equal to 50% throughout the surgery and received oxygen at 6l/min. upto 2 hrs postoperatively.
oxygen: Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery.
|
Total
n=60 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Customized
15-20 years
|
7 participants
n=99 Participants
|
8 participants
n=107 Participants
|
15 participants
n=206 Participants
|
|
Age, Customized
21-25 years
|
9 participants
n=99 Participants
|
10 participants
n=107 Participants
|
19 participants
n=206 Participants
|
|
Age, Customized
26-30
|
7 participants
n=99 Participants
|
7 participants
n=107 Participants
|
14 participants
n=206 Participants
|
|
Age, Customized
31-35
|
3 participants
n=99 Participants
|
2 participants
n=107 Participants
|
5 participants
n=206 Participants
|
|
Age, Customized
36-40
|
3 participants
n=99 Participants
|
2 participants
n=107 Participants
|
5 participants
n=206 Participants
|
|
Age, Customized
41-45
|
1 participants
n=99 Participants
|
1 participants
n=107 Participants
|
2 participants
n=206 Participants
|
|
Sex: Female, Male
Female
|
7 Participants
n=99 Participants
|
7 Participants
n=107 Participants
|
14 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
23 Participants
n=99 Participants
|
23 Participants
n=107 Participants
|
46 Participants
n=206 Participants
|
|
Body Mass Index
|
22.71 Kg/m^2
STANDARD_DEVIATION 3.17 • n=99 Participants
|
23.35 Kg/m^2
STANDARD_DEVIATION 4.25 • n=107 Participants
|
22.81 Kg/m^2
STANDARD_DEVIATION 3.7 • n=206 Participants
|
|
Body temperature
|
98.45 degrees Fahrenheit
STANDARD_DEVIATION 1.01 • n=99 Participants
|
98.67 degrees Fahrenheit
STANDARD_DEVIATION 1.16 • n=107 Participants
|
98.56 degrees Fahrenheit
STANDARD_DEVIATION 1.08 • n=206 Participants
|
|
Abdominal pain duration
|
1.33 days
STANDARD_DEVIATION 0.54 • n=99 Participants
|
1.87 days
STANDARD_DEVIATION 0.86 • n=107 Participants
|
1.60 days
STANDARD_DEVIATION 0.76 • n=206 Participants
|
|
Preoperative Haemoglobin
|
12.87 g/dL
STANDARD_DEVIATION 1.17 • n=99 Participants
|
13.07 g/dL
STANDARD_DEVIATION 1.57 • n=107 Participants
|
12.97 g/dL
STANDARD_DEVIATION 1.38 • n=206 Participants
|
|
Preoperative Total leucocyte count
|
12.20 10^3 cells per mm^3
STANDARD_DEVIATION 1.71 • n=99 Participants
|
13.30 10^3 cells per mm^3
STANDARD_DEVIATION 3.65 • n=107 Participants
|
12.75 10^3 cells per mm^3
STANDARD_DEVIATION 2.88 • n=206 Participants
|
|
Haemodynamic parameter
Stable
|
30 participants
n=99 Participants
|
30 participants
n=107 Participants
|
60 participants
n=206 Participants
|
|
Haemodynamic parameter
unstable
|
0 participants
n=99 Participants
|
0 participants
n=107 Participants
|
0 participants
n=206 Participants
|
|
Intraoperative pH
|
7.39 pH
STANDARD_DEVIATION 0.03 • n=99 Participants
|
7.40 pH
STANDARD_DEVIATION 0.05 • n=107 Participants
|
7.39 pH
STANDARD_DEVIATION 0.04 • n=206 Participants
|
|
Intraoperative partial pressure of arterial oxygen
|
86.53 mmHg
STANDARD_DEVIATION 3.52 • n=99 Participants
|
151.67 mmHg
STANDARD_DEVIATION 2.88 • n=107 Participants
|
119 mmHg
STANDARD_DEVIATION 3.86 • n=206 Participants
|
|
Intraoperative partial pressure of carbon dioxide
|
36.82 mmHg
STANDARD_DEVIATION 2.78 • n=99 Participants
|
36.16 mmHg
STANDARD_DEVIATION 6.46 • n=107 Participants
|
36.49 mmHg
STANDARD_DEVIATION 4.94 • n=206 Participants
|
|
Intraoperative bicarbonate
|
23.12 mmol/L
STANDARD_DEVIATION 1.2 • n=99 Participants
|
23.60 mmol/L
STANDARD_DEVIATION 3.39 • n=107 Participants
|
23.36 mmol/L
STANDARD_DEVIATION 2.53 • n=206 Participants
|
|
Intraoperative oxygen saturation
|
97.01 percentage of oxygenated haemoglobin
STANDARD_DEVIATION 5.20 • n=99 Participants
|
98.50 percentage of oxygenated haemoglobin
STANDARD_DEVIATION 1.08 • n=107 Participants
|
97.76 percentage of oxygenated haemoglobin
STANDARD_DEVIATION 3.80 • n=206 Participants
|
|
Intraoperative findings
Acute Appendicitis
|
29 participants
n=99 Participants
|
26 participants
n=107 Participants
|
55 participants
n=206 Participants
|
|
Intraoperative findings
Gangrenous Appendicitis
|
1 participants
n=99 Participants
|
4 participants
n=107 Participants
|
5 participants
n=206 Participants
|
|
Duration of surgery
|
1.05 Hours
STANDARD_DEVIATION .15 • n=99 Participants
|
1.14 Hours
STANDARD_DEVIATION .29 • n=107 Participants
|
1.1 Hours
STANDARD_DEVIATION .23 • n=206 Participants
|
|
Postoperative partial pressure of arterial oxygen
|
86.21 mmhg
STANDARD_DEVIATION 3.85 • n=99 Participants
|
137.6 mmhg
STANDARD_DEVIATION 2.49 • n=107 Participants
|
119 mmhg
STANDARD_DEVIATION 3.13 • n=206 Participants
|
|
Postoperative Total leucocyte count
|
8.16 10^3 cells per mm^3
STANDARD_DEVIATION 1.17 • n=99 Participants
|
9.03 10^3 cells per mm^3
STANDARD_DEVIATION 2.10 • n=107 Participants
|
8.6 10^3 cells per mm^3
STANDARD_DEVIATION 1.74 • n=206 Participants
|
|
Use of antibiotics
|
5.26 days
STANDARD_DEVIATION 1.11 • n=99 Participants
|
5.60 days
STANDARD_DEVIATION 1.27 • n=107 Participants
|
5.43 days
STANDARD_DEVIATION 1.19 • n=206 Participants
|
|
length of hospital stay
|
3.87 days
STANDARD_DEVIATION 1 • n=99 Participants
|
3.87 days
STANDARD_DEVIATION 1 • n=107 Participants
|
3.87 days
STANDARD_DEVIATION 1 • n=206 Participants
|
PRIMARY outcome
Timeframe: 14 daysASEPSIS score- Additional treatment; Serous discharge; Erythema; Purulent exudate; Separation of deep tissues; Isolation of bacteria; and Stay. A daily score of 20 or more considered evidence of infection. Category of infection: Total score of 0-10 satisfactory healing; 11-20 disturbance of healing; 21-30 minor wound infection; 31-40 moderate wound infection; \> 40 severe wound infection.
Outcome measures
| Measure |
Group A: Control
n=30 Participants
Group A: Control- Received no supplemental oxygen throughout the surgery and received oxygen at 4l/min. in 2hrs postoperatively
|
Group B: Test
n=30 Participants
Group B: Test- Received hyperoxygenation more than or equal to 50% throughout the surgery and received oxygen at 6l/min. upto 2 hrs postoperatively.
oxygen: Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery.
|
|---|---|---|
|
ASEPSIS Score
Satisfactory healing
|
30 participants
|
30 participants
|
|
ASEPSIS Score
Disturbance of healing
|
0 participants
|
0 participants
|
|
ASEPSIS Score
Minor wound infection
|
0 participants
|
0 participants
|
|
ASEPSIS Score
Moderate wound infection
|
0 participants
|
0 participants
|
|
ASEPSIS Score
Severe wound infection
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: 14 daysSonography; Pus culture; blood culture; Total Leucocyte Count.
Outcome measures
| Measure |
Group A: Control
n=30 Participants
Group A: Control- Received no supplemental oxygen throughout the surgery and received oxygen at 4l/min. in 2hrs postoperatively
|
Group B: Test
n=30 Participants
Group B: Test- Received hyperoxygenation more than or equal to 50% throughout the surgery and received oxygen at 6l/min. upto 2 hrs postoperatively.
oxygen: Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery.
|
|---|---|---|
|
Number of Patients Requiring Additional Investigations
Required
|
0 participants
|
0 participants
|
|
Number of Patients Requiring Additional Investigations
Not required
|
30 participants
|
30 participants
|
SECONDARY outcome
Timeframe: 14 daysRequirement of antipyretics; increased dose/ duration of antibiotic usage other than standard protocol; need for change to higher antibiotics; requirement of drainage procedures for pus/ wound infections; requirement for additional dressing sessions
Outcome measures
| Measure |
Group A: Control
n=30 Participants
Group A: Control- Received no supplemental oxygen throughout the surgery and received oxygen at 4l/min. in 2hrs postoperatively
|
Group B: Test
n=30 Participants
Group B: Test- Received hyperoxygenation more than or equal to 50% throughout the surgery and received oxygen at 6l/min. upto 2 hrs postoperatively.
oxygen: Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery.
|
|---|---|---|
|
Number of Patients Requiring Additional Treatment
Required
|
0 participants
|
0 participants
|
|
Number of Patients Requiring Additional Treatment
Not required
|
30 participants
|
30 participants
|
Adverse Events
Group A: Control
Group B: Test
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Swati Sattavan
Lady Hardinge Medical College and associated Hospitals
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place